• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

地区结核病中心耐多药结核病患者直接督导下短程化疗-加强治疗的药物不良反应及治疗结果分析:一项四年回顾性研究

Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.

作者信息

Dela Arif I, Tank Nitish Kumar D, Singh Anil P, Piparva Kiran G

机构信息

Department of Pharmacology, P.D.U. Government Medical College, Rajkot, Gujarat, India.

出版信息

Lung India. 2017 Nov-Dec;34(6):522-526. doi: 10.4103/0970-2113.217569.

DOI:10.4103/0970-2113.217569
PMID:29098997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5684809/
Abstract

BACKGROUND

Treatment of multidrug-resistant tuberculosis (MDR-TB) requires the use of expensive and toxic second-line anti-tubercular drugs which are given for a longer duration. Adverse drug reactions (ADRs) of second-line antitubercular drugs affect compliance and thereby treatment outcome. We set out to analyze ADRs and treatment outcome of MDR-TB patients receiving directly observed treatments plus therapy.

MATERIALS AND METHODS

A retrospective study of registered MDR-TB cases at district tuberculosis center during 2010-2014 was performed. Data regarding sociodemographic profile, diagnosis, and treatment as well as ADRs were recorded and evaluated. ADRs were evaluated for causality, severity assessment, management aspects, and impact on treatment outcome.

RESULTS

In total 147 ADRs were reported among 72 cases. Most commonly observed ADRs were gastrointestinal (24.5%) followed by self reported weakness (21.23%), psychological (14.38%), joint pain (14.38%), and respiratory symptoms. Discontinuation of the drugs due to ADRs was required in 36 (24.48%) events. ADRs were significantly associated with nontreatment adherence and defaulter outcome. Cure rate was higher in MDR-TB cases with ADRs (59.72%) than MDR-TB cases without ADRs (30.18%).

CONCLUSION

Attention needs to be paid for timely recognition and treatment of ADR with minimum modification of treatment regimen. Equal attention should be paid to MDR-TB without ADR cases to raise over all cure rate.

摘要

背景

耐多药结核病(MDR-TB)的治疗需要使用昂贵且有毒的二线抗结核药物,且用药时间更长。二线抗结核药物的药物不良反应(ADR)会影响依从性,进而影响治疗效果。我们着手分析接受直接观察治疗加其他疗法的耐多药结核病患者的药物不良反应及治疗效果。

材料与方法

对2010年至2014年期间在地区结核病中心登记的耐多药结核病病例进行回顾性研究。记录并评估有关社会人口统计学特征、诊断、治疗以及药物不良反应的数据。对药物不良反应进行因果关系评估、严重程度评估、管理方面评估以及对治疗效果的影响评估。

结果

72例患者中共报告了147例药物不良反应。最常观察到的药物不良反应是胃肠道反应(24.5%),其次是自述虚弱(21.23%)、心理反应(14.38%)、关节疼痛(14.38%)和呼吸道症状。36例(24.48%)事件因药物不良反应需要停药。药物不良反应与未坚持治疗及治疗失败结局显著相关。发生药物不良反应的耐多药结核病病例的治愈率(59.72%)高于未发生药物不良反应的耐多药结核病病例(30.18%)。

结论

需要注意及时识别和治疗药物不良反应,同时尽量减少治疗方案的调整。对于未发生药物不良反应的耐多药结核病病例也应给予同等关注,以提高总体治愈率。

相似文献

1
Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.地区结核病中心耐多药结核病患者直接督导下短程化疗-加强治疗的药物不良反应及治疗结果分析:一项四年回顾性研究
Lung India. 2017 Nov-Dec;34(6):522-526. doi: 10.4103/0970-2113.217569.
2
Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.在拉杰果德地区结核病中心对耐多药结核病(MDR-TB)患者采用直接观察治疗(DOT)联合方案的治疗效果及药物不良反应评估。
Perspect Clin Res. 2018 Oct-Dec;9(4):165-169. doi: 10.4103/picr.PICR_165_17.
3
Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.印度西部古吉拉特邦耐多药结核病方案停药的不良反应和危险因素。
Natl Med J India. 2020 Jan-Feb;33(1):10-14. doi: 10.4103/0970-258X.308234.
4
A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India.印度中部耐多药肺结核药物治疗方案不良反应的前瞻性观察研究。
Mediterr J Hematol Infect Dis. 2014 Sep 1;6(1):e2014061. doi: 10.4084/MJHID.2014.061. eCollection 2014.
5
Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania.坦桑尼亚一项评估N-乙酰半胱氨酸在降低耐多药结核病成人患者药物不良反应中的疗效、安全性和耐受性的可行性随机对照试验方案。
Pilot Feasibility Stud. 2023 Apr 1;9(1):55. doi: 10.1186/s40814-023-01281-7.
6
Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.耐多药结核病患者不良反应的发生、管理及危险因素。
Am J Ther. 2018 Sep/Oct;25(5):e533-e540. doi: 10.1097/MJT.0000000000000421.
7
Adverse drug reactions in tuberculosis and management.结核病中的药物不良反应及管理
Indian J Tuberc. 2019 Oct;66(4):520-532. doi: 10.1016/j.ijtb.2019.11.005.
8
Adverse drug reactions & drug interactions in MDR-TB patients.耐多药结核病患者的药物不良反应和药物相互作用。
Indian J Tuberc. 2020 Dec;67(4S):S69-S78. doi: 10.1016/j.ijtb.2020.09.027. Epub 2020 Oct 3.
9
Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.中国结核病患者直接观察治疗策略治疗的不良反应:一项前瞻性研究。
PLoS One. 2013 Jun 4;8(6):e65037. doi: 10.1371/journal.pone.0065037. Print 2013.
10
Treatment of multidrug-resistant tuberculosis in Thailand.泰国耐多药结核病的治疗
Chemotherapy. 1996;42 Suppl 3:10-5; discussion 30-3. doi: 10.1159/000239508.

引用本文的文献

1
Characterizing Musculoskeletal and Neurological Toxicities Associated With the BPaLM Regimen: A Clinical Evaluation of Arthralgia and Peripheral Neuropathy in Patients With Multidrug-Resistant Tuberculosis (MDR-TB).表征与BPaLM方案相关的肌肉骨骼和神经毒性:耐多药结核病(MDR-TB)患者关节痛和周围神经病变的临床评估
Cureus. 2025 Jun 17;17(6):e86248. doi: 10.7759/cureus.86248. eCollection 2025 Jun.
2
The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review.结核病治疗的不良反应:一项综合文献综述
Medicina (Kaunas). 2025 May 17;61(5):911. doi: 10.3390/medicina61050911.
3
..
IJID Reg. 2025 Mar 1;15:100615. doi: 10.1016/j.ijregi.2025.100615. eCollection 2025 Jun.
4
Adverse drug reactions and contributing factors in patients with drug-resistant tuberculosis: A 7-year retrospective cohort study in Addis Ababa, Ethiopia.耐多药结核病患者的药物不良反应及相关因素:埃塞俄比亚亚的斯亚贝巴的一项7年回顾性队列研究
J Clin Tuberc Other Mycobact Dis. 2025 Mar 5;39:100515. doi: 10.1016/j.jctube.2025.100515. eCollection 2025 May.
5
Treatment completion of drug-resistant tuberculosis in Ethiopia: A perspective from healthcare users.埃塞俄比亚耐多药结核病治疗的完成情况:来自医疗服务使用者的视角
PLOS Glob Public Health. 2025 Feb 7;5(2):e0004110. doi: 10.1371/journal.pgph.0004110. eCollection 2025.
6
Efficacy and safety profile of 2 line Anti TB drugs in DRTB patients in a tertiary care hospital of South Punjab.南旁遮普邦一家三级护理医院中二线抗结核药物在耐多药结核病患者中的疗效和安全性概况。
Pak J Med Sci. 2024 Dec;40(11):2665-2674. doi: 10.12669/pjms.40.11.8605.
7
Drug-resistant tuberculosis care and treatment outcomes over the last 15 years in Ethiopia: Results from a mixed-method review of trends.过去 15 年在埃塞俄比亚的耐药结核病护理和治疗结果:趋势的混合方法综述结果。
PLoS One. 2024 Aug 26;19(8):e0306076. doi: 10.1371/journal.pone.0306076. eCollection 2024.
8
Mortality rate and associated factors among patients co-infected with drug resistant tuberculosis/HIV at Mulago National Referral Hospital, Uganda, a retrospective cohort study.乌干达穆拉戈国家转诊医院耐多药结核病/艾滋病毒合并感染患者的死亡率及相关因素:一项回顾性队列研究
PLOS Glob Public Health. 2023 Jul 6;3(7):e0001020. doi: 10.1371/journal.pgph.0001020. eCollection 2023.
9
Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase).用于治疗耐多药结核病的药物安全性概况:基于世界卫生组织数据库(药物不良反应数据库)的描述性研究
Antibiotics (Basel). 2023 Apr 25;12(5):811. doi: 10.3390/antibiotics12050811.
10
Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda.耐多药结核病的药物不良反应及相关因素:乌干达姆巴拉拉地区转诊医院患者病历的回顾性研究
SAGE Open Med. 2023 May 3;11:20503121231171350. doi: 10.1177/20503121231171350. eCollection 2023.

本文引用的文献

1
Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam.越南胡志明市范玉塔医院国家结核病规划(NTP)内外耐多药结核病(MDR-TB)患者治疗中的不良事件。
BMC Res Notes. 2015 Dec 22;8:809. doi: 10.1186/s13104-015-1806-4.
2
Pyrazinamide-induced hyperuricemia.吡嗪酰胺诱发的高尿酸血症。
P T. 2014 Oct;39(10):695-715.
3
Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.俄罗斯托木斯克耐多药结核病患者的不良反应。
Int J Tuberc Lung Dis. 2007 Dec;11(12):1314-20.
4
Drug resistance in tuberculosis in India.印度结核病的耐药性
Indian J Med Res. 2004 Oct;120(4):377-86.
5
Psychiatric and neurological reactions to cycloserine in the treatment of tuberculosis.环丝氨酸治疗结核病时的精神和神经反应。
Dis Chest. 1957 Aug;32(2):172-82. doi: 10.1378/chest.32.2.172.
6
The diagnosis and management of multiple-drug-resistant-tuberculosis at the beginning of the new millenium.新千年伊始多重耐药结核病的诊断与管理
Int J Infect Dis. 2002 Mar;6 Suppl 1:S21-31. doi: 10.1016/s1201-9712(02)90151-7.
7
Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin.
Clin Infect Dis. 1993 Aug;17(2):288-9. doi: 10.1093/clinids/17.2.288.
8
Treatment of multidrug-resistant tuberculosis.耐多药结核病的治疗
N Engl J Med. 1993 Sep 9;329(11):784-91. doi: 10.1056/NEJM199309093291108.
9
The neurotoxicity of antibacterial agents.抗菌药物的神经毒性。
Ann Intern Med. 1984 Jul;101(1):92-104. doi: 10.7326/0003-4819-101-1-92.
10
Drug-induced psychiatric disorders.药物所致精神障碍
Drugs. 1981 Jul;22(1):57-69. doi: 10.2165/00003495-198122010-00004.